{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T17:51:21Z","timestamp":1697046681857},"reference-count":33,"publisher":"Cambridge University Press (CUP)","issue":"4","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"unspecified","delay-in-days":2906,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. psychiatr."],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S0924933800258185_abs1\" sec-type=\"other\"><jats:title>Purpose<\/jats:title><jats:p>To examine the relationship between different intervention approaches and subsequent real-life outcomes in patients changing treatment from escitalopram 10mg.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800258185_abs2\" sec-type=\"methods\"><jats:title>Method<\/jats:title><jats:p>This was a retrospective cohort study of patients starting antidepressant treatment between 2002 and 2004. Data were extracted from a US health-insurance reimbursement claims database. Eligible patients started escitalopram 10mg and changed within 3 months to: escitalopram \u226520mg; another antidepressant; or a combination of escitalopram with another antidepressant. Medication persistence and healthcare costs over 3 months were compared between the treatment groups.<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800258185_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Overall, 37,791 patients started escitalopram 10mg. Of the 12,830 patients (34%) who changed treatment, 56% increased escitalopram dose, 26% switched antidepressant and 18% combined escitalopram with another antidepressant. Patients in the switch and combination groups had significantly higher rates of non-persistence (56% and 91%, respectively) vs the dose-increase group (39%; both<jats:italic>P<\/jats:italic>&lt;0.001). Combination-group patients incurred significantly greater costs vs the dose-increase group ($2805 vs $1767, respectively;<jats:italic>P<\/jats:italic>&lt;0.001).<\/jats:p><\/jats:sec><jats:sec id=\"S0924933800258185_abs4\" sec-type=\"conclusions\"><jats:title>Conclusion<\/jats:title><jats:p>Results suggest that increasing escitalopram dose in patients responding inadequately to 10mg is associated with higher persistence rates vs the other treatment approaches. Receiving an increased dose of escitalopram was associated with significantly lower costs than combining escitalopram 10mg with another antidepressant.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.eurpsy.2010.08.009","type":"journal-article","created":{"date-parts":[[2010,10,31]],"date-time":"2010-10-31T08:44:25Z","timestamp":1288514665000},"page":"250-257","source":"Crossref","is-referenced-by-count":5,"title":["Increasing escitalopram dose is associated with fewer discontinuations than switch or combination approaches in patients initially on escitalopram 10mg"],"prefix":"10.1017","volume":"27","author":[{"given":"T.","family":"Sanglier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Milea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Saragoussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"S0924933800258185_bib24","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-8343(02)00201-3"},{"key":"S0924933800258185_bib19","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(01)01145-3"},{"key":"S0924933800258185_bib18","doi-asserted-by":"publisher","DOI":"10.1177\/070674370004500509"},{"key":"S0924933800258185_bib16","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900020320"},{"key":"S0924933800258185_bib13","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.106.s415.4.x"},{"key":"S0924933800258185_bib4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60046-5"},{"key":"S0924933800258185_bib31","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-007-0061-3"},{"key":"S0924933800258185_bib26","first-page":"1239","article-title":"Patterns of antidepressant use and their relation to costs of care.","volume":"2","author":"Thompson","year":"1996","journal-title":"Am J Manag Care."},{"key":"S0924933800258185_bib1","unstructured":"[1] American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder: Second edition; 2000. Available at: http:\/\/www.psychiatryonline.com\/pracGuide\/loadGuidelinePdf.aspx?file=MDD2e_Inactivated_04-16-09. [Last accessed on 3 June 2009]."},{"key":"S0924933800258185_bib22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052963"},{"key":"S0924933800258185_bib20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7370.934"},{"key":"S0924933800258185_bib14","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.617"},{"key":"S0924933800258185_bib21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.04.005"},{"key":"S0924933800258185_bib33","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.7.1285"},{"key":"S0924933800258185_bib28","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.1.28"},{"key":"S0924933800258185_bib25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1176\/ajp.152.3.352","article-title":"Health care costs associated with depressive and anxiety disorders in primary care.","volume":"152","author":"Simon","year":"1995","journal-title":"Am J Psychiatry."},{"key":"S0924933800258185_bib29","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200009000-00005"},{"key":"S0924933800258185_bib10","doi-asserted-by":"publisher","DOI":"10.1176\/foc.3.1.34"},{"key":"S0924933800258185_bib17","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.55.12.1128"},{"key":"S0924933800258185_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.18553\/jmcp.2005.11.2.145","article-title":"Relationship of total health care changes to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy\u2013results from a managed care administrative claims database.","volume":"11","author":"Eaddy","year":"2005","journal-title":"J Manag Care Pharm."},{"key":"S0924933800258185_bib23","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(96)00100-0"},{"key":"S0924933800258185_bib15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.18553\/jmcp.2008.14.5.426","article-title":"Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.","volume":"14","author":"Khandker","year":"2008","journal-title":"J Manag Care Pharm."},{"key":"S0924933800258185_bib6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.01025.x"},{"key":"S0924933800258185_bib27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2008.07.004"},{"key":"S0924933800258185_bib32","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)70391-0"},{"key":"S0924933800258185_bib9","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(05)70283-5"},{"key":"S0924933800258185_bib2","unstructured":"[2] Asnis G, Tsai J, Dworak H, Mao Y. Fixed-dose comparison of escitalopram and duloxetine in severely depressed people. Presented at the 26th Biennial Congress of the Collegium Internationale Neuro-Psychopharmacologicum, Munich, Germany, 13\u201317 July, 2008 [Poster No. P-04.56]."},{"key":"S0924933800258185_bib5","first-page":"593","article-title":"The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts.","volume":"30","author":"Crystal","year":"1995","journal-title":"Health Serv Res."},{"key":"S0924933800258185_bib12","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1211"},{"key":"S0924933800258185_bib3","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A254"},{"key":"S0924933800258185_bib11","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0602"},{"key":"S0924933800258185_bib8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.03.012"},{"key":"S0924933800258185_bib30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2008.09.008"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933810001653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933810001653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933800258185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T22:25:00Z","timestamp":1636755900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933800258185\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0924933800258185"],"URL":"https:\/\/doi.org\/10.1016\/j.eurpsy.2010.08.009","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}